Literature DB >> 16498194

Literature review, case report, and expert discussion of prolonged refractory status epilepticus.

T K Robakis1, L J Hirsch.   

Abstract

We report the case of a 30-year-old woman with severe, prolonged refractory status epilepticus requiring more than 6 months of iatrogenic coma. Opinions on prognosis and clinical management were solicited from a number of experienced neurointensivists and epileptologists at multiple time-points during the clinical course. The ensuing discussion, annotated with references, is presented here. Several experts commented on isolated cases of young patients with encephalitis requiring up to 2-3 months of iatrogenic coma, yet still having good outcomes. Treatments discussed include ketamine, gammaglobulin, plasmapheresis, steroids, adrenocorticotropic hormone, very high-dose phenobarbital, isoflurane, lidocaine, electroconvulsive therapy, ketogenic diet, hypothermia, magnesium, transcranial magnetic stimulation, vagus nerve stimulation, deep brain stimulation, and neurosurgery. The patient eventually suffered a cardiac arrest but was resuscitated as requested by the family. Seizures then stopped, and the patient has remained in a persistent vegetative state since.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16498194     DOI: 10.1385/NCC:4:1:035

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.210


  40 in total

1.  Prolonged treatment for acute symptomatic refractory status epilepticus: outcome in children.

Authors:  Mustafa Sahin; Caroline C Menache; Gregory L Holmes; James J Riviello
Journal:  Neurology       Date:  2003-08-12       Impact factor: 9.910

2.  Comparison of CT scan and MRI findings in the diagnosis of Japanese encephalitis.

Authors:  J Kalita; U K Misra
Journal:  J Neurol Sci       Date:  2000-03-01       Impact factor: 3.181

3.  Ketamine, phencyclidine, and MK-801 protect against kainic acid-induced seizure-related brain damage.

Authors:  D B Clifford; J W Olney; A M Benz; T A Fuller; C F Zorumski
Journal:  Epilepsia       Date:  1990 Jul-Aug       Impact factor: 5.864

Review 4.  The use of immunoglobulins in the treatment of human epilepsy.

Authors:  F Villani; G Avanzini
Journal:  Neurol Sci       Date:  2002-04       Impact factor: 3.307

5.  Diffusion-weighted magnetic resonance imaging abnormalities in Bartonella encephalopathy.

Authors:  Aneesh B Singhal; Michael C Newstein; Ronald Budzik; Jang-Ho Cha; Guy Rordorf; Ferdinando S Buonanno; Michael A Panzara
Journal:  J Neuroimaging       Date:  2003-01       Impact factor: 2.486

Review 6.  Autoimmune disorders of neuronal potassium channels.

Authors:  John Newsom-Davis; Camilla Buckley; Linda Clover; Ian Hart; Paul Maddison; Erdem Tüzüm; Angela Vincent
Journal:  Ann N Y Acad Sci       Date:  2003-09       Impact factor: 5.691

7.  Relapse and survival after barbiturate anesthetic treatment of refractory status epilepticus.

Authors:  K B Krishnamurthy; F W Drislane
Journal:  Epilepsia       Date:  1996-09       Impact factor: 5.864

8.  Oral ketamine in paediatric non-convulsive status epilepticus.

Authors:  L D Mewasingh; T Sékhara; A Aeby; F J C Christiaens; B Dan
Journal:  Seizure       Date:  2003-10       Impact factor: 3.184

9.  Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis.

Authors:  Angela Vincent; Camilla Buckley; Jonathan M Schott; Ian Baker; Bonnie-Kate Dewar; Niels Detert; Linda Clover; Abigail Parkinson; Christian G Bien; Salah Omer; Bethan Lang; Martin N Rossor; Jackie Palace
Journal:  Brain       Date:  2004-02-11       Impact factor: 13.501

10.  Very-high-dose phenobarbital for refractory status epilepticus in children.

Authors:  T O Crawford; W G Mitchell; L S Fishman; S R Snodgrass
Journal:  Neurology       Date:  1988-07       Impact factor: 9.910

View more
  20 in total

Review 1.  Management of refractory status epilepticus in adults: still more questions than answers.

Authors:  Andrea O Rossetti; Daniel H Lowenstein
Journal:  Lancet Neurol       Date:  2011-10       Impact factor: 44.182

Review 2.  Posterior reversible encephalopathy syndrome in intensive care medicine.

Authors:  Giuseppe Servillo; Francesca Bifulco; Edoardo De Robertis; Ornella Piazza; Pasquale Striano; Fabio Tortora; Salvatore Striano; Rosalba Tufano
Journal:  Intensive Care Med       Date:  2006-11-21       Impact factor: 17.440

3.  Status epilepticus.

Authors:  Panayiotis N Varelas; Marek A Mirski
Journal:  Curr Neurol Neurosci Rep       Date:  2009-11       Impact factor: 5.081

4.  Ketamine for Refractory Status Epilepticus: A Systematic Review.

Authors:  Anna Rosati; Salvatore De Masi; Renzo Guerrini
Journal:  CNS Drugs       Date:  2018-11       Impact factor: 5.749

Review 5.  Treatment of Refractory and Super-refractory Status Epilepticus.

Authors:  Samhitha Rai; Frank W Drislane
Journal:  Neurotherapeutics       Date:  2018-07       Impact factor: 7.620

6.  Ethics roundtable: 'Open-ended ICU care: can we afford it?'.

Authors:  David Crippen; Dick Burrows; Nino Stocchetti; Stephan A Mayer; Peter Andrews; Tom Bleck; Leslie Whetstine
Journal:  Crit Care       Date:  2010-06-21       Impact factor: 9.097

7.  Prolonged refractory status epilepticus related to thrombotic thrombocytopenic purpura.

Authors:  Alexander Y Zubkov; Alejandro A Rabinstein; Edward M Manno; Eelco F M Wijdicks
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

Review 8.  NMDA antagonists for refractory seizures.

Authors:  F A Zeiler; J Teitelbaum; L M Gillman; M West
Journal:  Neurocrit Care       Date:  2014-06       Impact factor: 3.210

9.  The role of neurosurgery in status epilepticus.

Authors:  Yu-Tze Ng; Ruth E Bristol; Dewi V Schrader; Kris A Smith
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.210

10.  Bowel ischemia: a rare complication of thiopental treatment for status epilepticus.

Authors:  Carlo Cereda; Mette M Berger; Andrea O Rossetti
Journal:  Neurocrit Care       Date:  2008-11-25       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.